---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-060319"
form_type: "8-K"
ticker: "RBOT"
cik: "0001812173"
company_name: "Vicarious Surgical Inc."
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:49:30.273095+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Vicarious Surgical updates corporate presentation, targeting 2025 launch vs $150B market

## Summary
- $150B addressable abdominal market; 96% of procedures still manual per company estimates.
- Partnerships with three leading health systems (HCA, UPMC, etc.) covering >200 hospitals.
- Roadmap: Beta 2 build in 2023, version 1.0 design lock and FDA De Novo submission in 2024.
- First clinical patient expected in 2024, commercial launch targeted for 2025.
- Decoupled actuator technology enables 1.8cm single-port access with 13 degrees of freedom per arm.

## SEC filing metadata
- accession: 0001213900-23-060319
- form_type: 8-K
- ticker: RBOT
- cik: 0001812173
- company_name: Vicarious Surgical Inc.
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812173/000121390023060319/0001213900-23-060319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812173/000121390023060319/ea182474-8k_vicarious.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-060319
- JSON: https://secwatch.observer/filing/0001213900-23-060319.json
- Plain text: https://secwatch.observer/filing/0001213900-23-060319.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.